ALDH18A1 encodes P5CS (pyrroline-5-carboxylate synthase), a bifunctional enzyme that catalyzes the rate-limiting step in proline biosynthesis by converting glutamate to glutamate 5-semialdehyde 1. This enzyme plays a crucial role in amino acid metabolism, particularly in the glutamine-arginine-proline metabolic axis 2. P5CS functions as a major consumer of glutamate and enables cancer cells to adapt to nutrient stress by promoting de novo glutamine synthesis when proline biosynthesis is reduced 1. The enzyme has been identified as a metabolic target in cancer, with expression regulated by histone acetylation in hepatocellular carcinoma 3 and serving as a potential angiogenic target 4. ALDH18A1 mutations cause multiple genetic disorders including autosomal recessive cutis laxa type 3A and hereditary spastic paraplegia (SPG9A/9B) 56. Patients with ALDH18A1 mutations present with diverse clinical features including cutis laxa, joint laxity, developmental delays, microcephaly, and neurological involvement 6. The enzyme's role in metabolic reprogramming makes it an attractive therapeutic target for cancer treatment 27.